Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Lenalidomide
Drug: Prednisone
Drug: Dexamethasone

Registration Number: NCT01054144

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Brief Summary: The purpose of this research is to estimate the effectiveness of a response adapted approach with the use of the drug, lenalidomide in the treatment of older adults with newly diagnosed standard risk multiple myeloma. This means that participants will be given the study drug, lenalidomide but depending on how they respond to this drug they may also be given dexamethasone and/or prednisone to help with their treatment.

Detailed Description: Summary: Patients will be started on the study drug, lenalidomide on Day 1, Cycle 1. Lenalidomide is a capsule that is to be taken orally (by mouth). If the patient's disease progresses after 2 cycles of therapy, a low dose of dexamethasone will be added. If the patient's disease is stable after 2 cycles of therapy, the use of an alternate corticosteroid (prednisone) will be added to the lenalidomide therapy they are receiving. Dexamethasone and prednisone are in tablet form and will be taken orally (by mouth). However, if the patient has a minimal response after an additional 2 cycles of lenalidomide therapy, the therapy will be continued until their disease progresses. See the intervention descriptions for further details.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 27

Inclusion Criteria

Understand and voluntarily sign an informed consent form
Age ≥65 years or not eligible for high dose therapy and autologous stem cell transplant
Able to adhere to study visit schedule and other protocol requirements
Diagnosed with multiple myeloma and considered to have active disease. Patients must not have received an active chemotherapy regimen or Dexamethasone. Patients may have received palliative radiotherapy at least 2 weeks prior to the study start.
Measurable myeloma paraprotein levels in serum (≥ 0.5 g/dL), urine (≥ 0.2 g excreted in a 24-hour urine collection sample) or by serum free light chains (involved free light chain greater than 100mg/L)
Eastern Cooperative Group (ECOG) Performance Status of 0 or 1
Serum bilirubin levels ≤1.5 times the upper limit of the normal (ULN) range for the laboratory
Serum aspartate transaminase (AST) or serum alanine transaminase (ALT) levels ≤2 x ULN
Adequate bone marrow function: Absolute neutrophil count ≥ 1,000 cells/mm³ (1.0 x 10^9/L); Platelets ≥ 100,000 /mm³
Hemoglobin > 8 g/dL
Adequate renal function: Calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula
Low risk myeloma is defined as the absence of the following adverse features[21]: t(4;14) by FISH or metaphase cytogenetics; t(14,16) or t(14;20) by FISH or metaphase cytogenetics; Deletion 17q13 by FISH; Deletion 13 by metaphase analysis; Aneuploidy by metaphase analysis; Β2 microglobulin > 5.5.
Able to tolerate one of the following thromboprophylactic strategies: aspirin, low molecular weight heparin or warfarin (coumadin)
Must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli-international units per milliliter (mIU/mL) within 10 14 days prior to and again within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a female of child bearing potential even if they have had a successful vasectomy.

Exclusion Criteria

Ongoing severe infection requiring intravenous antibiotic treatment
Life expectancy of less than 3 months
Performance status of 2, 3 or 4
Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer from which the patient has been disease-free for at least 2 years
Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia
Uncontrolled medical problems such as diabetes mellitus, congestive heart failure, coronary artery disease, hypertension, unstable angina, arrhythmias), pulmonary, hepatic and renal diseases unless renal insufficiency is felt to be secondary to multiple myeloma.
Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
Pregnant or lactating
Any condition, including the presence of laboratory abnormalities, which places the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
Known hypersensitivity to thalidomide
Use of any other experimental drug or therapy within 28 days of baseline.
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
Any prior use of lenalidomide
Concurrent use of other anti-cancer agents or treatments
Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Response Adapted Therapy	Lenalidomide	Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.
Response Adapted Therapy	Dexamethasone	Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.
Response Adapted Therapy	Prednisone	Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.

Primary Outcome Measures

Name	Time	Method
Combined Therapy - Median Progression Free Survival	up to 36 months	Progression free survival (PFS) of older adults with mildly symptomatic multiple myeloma treated on this response adapted approach (i.e. time from start of lenalidomide to failure of lenalidomide and low dose dexamethasone)

Secondary Outcome Measures

Name	Time	Method
Response Rate	Every 8 weeks up to 12 months	Response rate in older adults with mildly symptomatic multiple myeloma to single agent lenalidomide, lenalidomide prednisone and lenalidomide low dose dexamethasone in patients with suboptimal responses to lenalidomide monotherapy. The study used the uniform response assessment of the International Myeloma Working Group with the addition of MR (minimal response) (Durie et al, 2006; Kumar et al, 2016). MR was defined as a 25-49% decrease in serum M spike, and a 50-89% improvement in urine M spike. For patients without a measurable serum or urine M spike, a 25-49% decrease in the difference between the involved and uninvolved free light chains was required. The response in this trial is defined as complete remission (CR), stringent complete remission (SRC), very good partial remission (VGPR) and partial remission (PR) and minimal response (MR).
Number of Participants With 1 Year Overall Survival (OS)	1 Year	The 1 year overall survival of older adults with mildly symptomatic multiple myeloma treated on this response adapted approach
Number of Participants With Serious Adverse Events	Day 1 through Off Study Date, an average of 48 months	Number of participants with serious adverse events
Single Agent - Median Progressive Free Survival (PFS)	First measure at 8 weeks	The progression free survival of patients treated with single agent lenalidomide